Anti Tumor Drugs Market Size, Industry Trends Report | 2031

Segments - Anti-tumor Drugs Market by Types (Blood Cancer, Lung Cancer, Breast Cancer, and Others), Applications (Chemotherapy, Targeted Therapy [Monoclonal Antibody and Small Molecule Drugs], Surgical, Radiation, and Immunotherapy), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023-2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Anti-tumor Drugs Market Outlook 2031

The global anti-tumor drugs market size was USD XX Billion in 2022 and is projected to reach USD XX Billion by 2031 register a substantial CAGR XX% during the forecast period, 2023-2031. attributed to upcoming patents, continuous development going on in the medicinal field, and its increasing demand. Moreover, increase in the incidence of cancer cases globally is also expected to boost market growth.

The abnormal proliferation of tissues cause tumors. Genetic mutations can be a cause of abnormal proliferation of tissues. A type of drug that is used to block the growth of cancer cells by interfering with DNA is known as the anti-tumor drugs.

These drugs are also widely known as anticancer drugs. Reports by the World Health Organization (WHO) state that the number of cancer cases is expected to reach 15 million by 2025. Similarly, a fact sheet by the Globocan 2020 stated that nearly 19,292,789 new cancer cases were diagnosed globally and around 9,958,133 deaths took place due to cancer.

The COVID-19 pandemic outbreak had a negative impact on the global anti-tumor drugs market attributed to sudden shift of focus of pharmaceutical and medical institutions on preventing the widespread of the COVID infection. The article published in the Cancer Connect 2020 suggested that the diagnosis of the most common cancers including blood cancer, lung cancer, breast cancer, and others had been decreased by 46% during the early phase of the pandemic.

The screening of the cancer is also sparsely done as many hospitals utilize their infrastructures for the treatment of patients infected with COVID-19. However, it is anticipated that the situation will improve gradually in the post-COVID situation.

Anti-tumor Drugs Market Trends, Drivers, Restraints, and Opportunities

Increasing urge for personalized medicines and growing patient assistance program are key factors helping the market growth over the forecast period.
Rising approvals of new drugs and high research activities associated with targeted therapies are another factors driving the growth expansion.
Increasing initiatives by prominent players for strong research & development is expected to fuel the market growth in the coming years.
Cancer therapies are high in cost and the fluctuation in reimbursement policies are anticipated to act as restraining points that can hamper the market growth.
Increasing initiatives by the government to create awareness about early diagnosis of cancer is a key opportunity for the market during the forecast period.

Scope of Anti-tumor Drugs Market Report

The report on the global anti-tumor drugs market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Anti-tumor Drugs Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Types (Blood Cancer, Lung Cancer, Breast Cancer, and Others) and Applications (Chemotherapy, Targeted Therapy [Monoclonal Antibody and Small Molecule Drugs], Surgical, Radiation, and Immunotherapy)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Roche; Celgene; and Novartis

Anti-tumor Drugs Market Segment Insights

Blood cancer segment is anticipated to hold a large market share

On the basis of types, the global anti-tumor drugs market is divided into blood cancer, lung cancer, breast cancer, and others. The blood cancer segment is anticipated to hold a large share of the market during the forecast period attributed to the high cost of therapies and wide prevalence of the type of cancer worldwide.

Targeted therapy segment is expected to hold a significant share

Based on applications, the market is segmented into chemotherapy, targeted therapy, surgical, radiation, and immunotherapy. The targeted therapy segment is further bifurcated into monoclonal antibody and small molecule drugs. The targeted therapy segment is expected to hold a significant share during the forecast period of the market attributed to increasing in research & development.

Targeted therapy are drugs that are engineered especially that act only in the targeted regions without causing little to no harm to the surrounding area. Several research and technological innovations are taking place in the field of biotechnology in order to increase the availability and effectiveness of monoclonal antibody drugs.

Monoclonal antibody drugs include panitumumab and rituximab while drugs such as imatinib is used for immunotherapy that helps to stimulate the immune system of an individual against cancer cells. The immunotherapy segment is expected to boost at an impressive growth rate during the projected period.

Asia Pacific market is estimated to expand at a substantial rate

In terms of regions, the global anti-tumor drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to hold a major share of the market in the coming years owing to wide number of cancer patients and high adoption of drugs among a large number of the targeted population in the region.

However, the market of Asia Pacific is estimated to expand at a substantial rate in the coming years attributed to lack of availability of drugs and high mortality due to cancer in the region.

Segments

The global anti-tumor drugs market has been segmented on the basis of

Types

Blood Cancer
Lung Cancer
Breast Cancer
Others

Applications

Chemotherapy
Targeted Therapy
- Monoclonal Antibody
- Small Molecule Drugs
Surgical
Radiation
Immunotherapy

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Competitive Landscape

Key players competing in the global anti-tumor drugs market are Roche; Celgene; and Novartis. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their consumer base and expand their market position globally.

For instance, the oncology unit of GlaxoSmithKline was acquired by Novartis to expand the development of innovative cancer treatment drugs.

Global Anti Tumor Drugs Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-tumor Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Anti-tumor Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Anti-tumor Drugs Market - Supply Chain
  4.5. Global Anti-tumor Drugs Market Forecast
     4.5.1. Anti-tumor Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Anti-tumor Drugs Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Anti-tumor Drugs Market Absolute $ Opportunity
5. Global Anti-tumor Drugs Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Anti-tumor Drugs Market Size and Volume Forecast by Types
     5.3.1. Blood Cancer Lung Cancer Breast Cancer Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Anti-tumor Drugs Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Anti-tumor Drugs Market Size and Volume Forecast by Applications
     6.3.1. Chemotherapy Targeted Therapy Surgical Radiation Immunotherapy
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Anti-tumor Drugs Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Anti-tumor Drugs Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Anti-tumor Drugs Demand Share Forecast, 2019-2026
8. North America Anti-tumor Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Anti-tumor Drugs Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Anti-tumor Drugs Market Size and Volume Forecast by Types
     8.4.1. Blood Cancer Lung Cancer Breast Cancer Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Anti-tumor Drugs Market Size and Volume Forecast by Applications
     8.7.1. Chemotherapy Targeted Therapy Surgical Radiation Immunotherapy
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Anti-tumor Drugs Demand Share Forecast, 2019-2026
9. Latin America Anti-tumor Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Anti-tumor Drugs Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Anti-tumor Drugs Market Size and Volume Forecast by Types
     9.4.1. Blood Cancer Lung Cancer Breast Cancer Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Anti-tumor Drugs Market Size and Volume Forecast by Applications
     9.7.1. Chemotherapy Targeted Therapy Surgical Radiation Immunotherapy
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Anti-tumor Drugs Demand Share Forecast, 2019-2026
10. Europe Anti-tumor Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Anti-tumor Drugs Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Anti-tumor Drugs Market Size and Volume Forecast by Types
     10.4.1. Blood Cancer Lung Cancer Breast Cancer Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Anti-tumor Drugs Market Size and Volume Forecast by Applications
     10.7.1. Chemotherapy Targeted Therapy Surgical Radiation Immunotherapy
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Anti-tumor Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Anti-tumor Drugs Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Anti-tumor Drugs Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Anti-tumor Drugs Market Size and Volume Forecast by Types
     11.4.1. Blood Cancer Lung Cancer Breast Cancer Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Anti-tumor Drugs Market Size and Volume Forecast by Applications
     11.7.1. Chemotherapy Targeted Therapy Surgical Radiation Immunotherapy
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Anti-tumor Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Anti-tumor Drugs Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Anti-tumor Drugs Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Anti-tumor Drugs Market Size and Volume Forecast by Types
     12.4.1. Blood Cancer Lung Cancer Breast Cancer Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Anti-tumor Drugs Market Size and Volume Forecast by Applications
     12.7.1. Chemotherapy Targeted Therapy Surgical Radiation Immunotherapy
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Anti-tumor Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Anti-tumor Drugs Market: Market Share Analysis
  13.2. Anti-tumor Drugs Distributors and Customers
  13.3. Anti-tumor Drugs Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Roche Celgene Novartis